NEXT UP
Claudia McGloin asks: what should really define the next trend in regenerative injectables?
If you work in aesthetics long enough, you quickly learn that there is always a “next big thing”. Regenerative aesthetics is no different. PRP, PRF, polynucleotides, exosomes, biostimulators and complex combination treatments are now competing for attention in a rapidly expanding market.
I am all for innovation, but after many years working with PRP and regenerative treatments, I have become increasingly cautious about confusing new with better.
Innovation is how medicine progresses, but adopting something simply because it is new is very different from adopting it because there is a sound clinical reason to do so. With regenerative treatments in particular, terminology can be persuasive. The word “regenerative” suggests repair, restoration and biological improvement, but describing a treatment as regenerative does not automatically mean regeneration is occurring.
So perhaps instead of asking what is trending, we should be asking some more fundamental questions.
Those questions may not be the most exciting questions when a new product launches, but they are the questions that should determine whether a treatment becomes part of our clinical practice.
COMBINATION REGENERATIVE TREATMENTS
One trend I do think we will continue to see is the growth of combination regenerative treatments. We are moving away from relying on one injectable or one modality to address everything and towards combining treatments with different proposed mechanisms of action.
There is logic to this. Ageing is multifactorial. Hair loss is multifactorial. Tissue quality, vascularity, inflammation, cellular function and the underlying health of the patient can all influence what we are trying to achieve. It makes sense that one intervention may not address every component.
But combination therapy should not simply mean adding more treatments.
When combining PRP with another injectable, device or regenerative modality, I want to understand what each contributes, the evidence or biological rationale for the combination, the optimal sequencing and any additional risks.
Without those questions, combination therapy can very quickly become treatment stacking.
NEWER DOES NOT MEAN BETTER
PRP itself provides a useful example of why newer does not necessarily mean better. Despite being one of the more established regenerative treatments, we are still refining our understanding of it.
We still talk about PRP as though it were one treatment, when two practitioners can take blood from two different patients, use two different preparation systems and produce biologically very different products. Platelet concentration, leucocyte content, red blood cell contamination, processing and activation can all vary. That is before we even consider the indication, injection technique or perhaps the greatest variable of all, the patient.
If we have not yet completely standardised how we describe and use one of our most established regenerative treatments, we should perhaps be cautious about how quickly we embrace the next one.
PROFESSIONAL RESPONSIBILITY
There is also a professional responsibility that comes with introducing new injectable treatments. Learning how to inject a product is only one part of being competent to offer it. We need to understand what we are using, the evidence behind it, appropriate indications and contraindications, patient selection, consent, potential complications and what we will do when something does not go according to plan.
Marketing should never move faster than competence.
Perhaps this is where the real trend in regenerative aesthetics needs to occur.
Instead of continually asking, “What is the next injectable?”, perhaps we should be asking, “What represents genuine progress?”
Sometimes that will be a new product. Sometimes it will be a new combination or a better understanding of how existing treatments can work together. But progress can also mean becoming more selective, questioning claims, recognising when the evidence is not yet sufficient and using the regenerative treatments we already have more intelligently.
The treatments that ultimately become established clinical practice should not be those that generate the most attention or the greatest hype. They should be the treatments that withstand scrutiny, have a clear clinical rationale and ultimately demonstrate value for our patients.
The future of regenerative injectables should not be defined by what is newest.
It should be defined by what improves patient outcomes.
CLAUDIA MCGLOIN
Claudia McGloin is a registered nurse with dual registration in Ireland and the UK and over 28 years of clinical nursing experience. An orthopaedic nurse practitioner specialising in PRP and regenerative medicine, she works across regenerative aesthetics, musculoskeletal medicine and patient optimisation. Claudia is an international speaker, educator and an Aesthetic Medicine editorial contributor.